Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
| ID | Título | Última Revisión | Siguiente Revisión | Descripción | Acceso |
|---|---|---|---|---|---|
| 07.001.066 | Risk-Reducing Mastectomy | Oct 16, 2025 | Oct 20, 2026 | Risk-reducing mastectomy is defined as the removal of the breast in the absence of malignant disease to... | Ver |
| 11.003.027 | Gene Variants Associated With Breast Cancer In Individuals At High Breast Cancer Risk. | Sep 11, 2025 | Sep 20, 2026 | It is estimated that 3% to 5% of women presenting for assessment for hereditary breast/ovarian cancer risk... | Ver |
| 11.003.030 | Genetic Testing For Brca1 Or Brca2 For Hereditary Breast/Ovarian Cancer Syndrome And Other High-Risk Cancers | Sep 19, 2025 | Sep 20, 2026 | Hereditary breast and ovarian cancer syndrome describes the familial cancer syndromes related to variants in... | Ver |
| 11.003.036 | Genetic Testing For Familial Cutaneous Malignant Melanoma | Apr 18, 2025 | Apr 20, 2026 | Cutaneous melanoma is the third most common type of skin cancer, but the most lethal. some cases of cutaneous... | Ver |
| 11.003.048 | Carrier Screening For Genetic Diseases | Oct 10, 2025 | Oct 20, 2026 | Carrier screening is performed to identify individuals at risk of having offspring with inherited recessive... | Ver |
| 11.003.064 | Genetic Cancer Susceptibility Panels Using Next Generation Sequencing | Nov 10, 2025 | Nov 20, 2026 | Commercially available cancer susceptibility gene panels can test for multiple variants associated with a... | Ver |
| 11.003.098 | Use Of Common Genetic Variants (Single Nucleotide Variants) To Predict Risk Of Nonfamilial Breast Cancer | Nov 12, 2025 | Nov 20, 2026 | Several single nucleotide variants (snvs), which are single base-pair variations in the dna sequence of the... | Ver |
| 11.003.107 | Genetic Testing For Hereditary Pancreatic Cancer | Mar 03, 2025 | Mar 20, 2026 | Pancreatic cancer is the fourth leading cause of cancer death in the united states, accounting for 8.3% of... | Ver |
| 11.003.134 | Molecular Testing For Variants Associated With Hereditary Ovarian Cancer | Sep 02, 2025 | Sep 20, 2026 | It is estimated that approximately 20% of women presenting for assessment for hereditary ovarian cancer (oc)... | Ver |
| 11.003.135 | Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Breast Cancer | Jan 20, 2025 | Jan 20, 2026 | Multiple biomarkers are being evaluated to predict response to targeted treatments for patients with advanced... | Ver |
| 11.003.137 | Germline Genetic Testing for Hereditary Diffuse Gastric Cancer (CDH1, CTNNA1) | Sep 22, 2025 | Sep 20, 2026 | Hereditary diffuse gastric cancer (hdgc, sometimes called signet ring gastric cancer) is an autosomal... | Ver |
| 11.003.138 | Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, Microsatellite Instability/Mismatch Repair, Tumor Mutational Burden) | Oct 16, 2025 | Oct 20, 2026 | Biomarker-targeted therapy has shown a clear survival benefit in individuals with metastatic prostate cancer.... | Ver |
| 11.003.139 | Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Ovarian Cancer (BRCA1, BRCA2, Homologous Recombination Deficiency, Tumor Mutational Burden, Microsatellite Instability/Mismatch Repair) | Oct 16, 2024 | Oct 20, 2025 | Biomarker-targeted therapy has shown a clear survival benefit in patients with ovarian cancer. more recently,... | Ver |
